Cathy Eng, MD

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses surgical considerations for patients with RAS-mutant colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the impact of RAS mutations on outcomes in patients with early vs late colorectal cancer following liver resection.

Cathy Eng, MD, FACP, FASCO, discusses results from the extended RAS analysis of the phase 3 EPIC trial in patients with metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.